Companies

INVENesis Sàrl

Contact

Jean-Luc Perret
Managing Director
jean-luc.perret@invenesis.com
 

 

Elodie Valazza Rufener
CFO
elodie.valazza@invenesis.com
 
 
Maladière 71
2000 Neuchâtel
 
info@invenesis.com
www.invenesis.com


 

INVENesis is a swiss biotechnology company based in Neuchâtel created in March 2017. We provide R&D services for drug discovery as well as the technology allowing our clients to generate their own intellectual property.

We position ourselves as an agile structure, part of an ecosystem of companies who look for drugs, pheromones, bio-control, biologics and customized technologies for applications in parasitology, agriculture and human medicine. Our clients are industrial partners active in the Animal Health, Plant Protection (Crop) and Pharmaceutical fields as well as with academic institutes. 

Our expertise is based on 3 technology platforms: 

  • Electrophysiology (on oocytes or arthropods)
  • Model organism and parasite based in-vitro assays (C. elegans, D. melanogaster, ecto- and endoparasites)
  • Custom R&D services (protocols, molecular biology, development of hardwares and softwares) 

Automation and miniaturization of our assays provide high quality data at competitive prices with minimal amounts of compounds. Most assays are scalable up to high throughput screening allowing to screen libraries containing millions of compounds. Our tests can also be used to identify the mode(s) of action and secondary effects of compounds.

Our team is composed of passionate experts with a cumulated multidisciplinary know-how of more than 50 years in pharmaceutical research. INVENesis is the partner of choice to carry out your research in total confidentiality. 

Target markets:

Pharmaceutical companies, Animal Heath, Plant Protection (Crops) and academic institutes

Key words:

Research, R&D, CRO, services, drug discovery, screening, electrophysiology, molecular biology, genetic engineering, phentoypic screens, parasitology, ion channels, robotics, machine vision, experimental protocols, miniaturisation

Financing:

Private